about
PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular LymphomasImaging biomarker roadmap for cancer studiesApplications of positron emission tomography in neuro-oncology: a clinical approach.Retrospective data-driven respiratory gating for PET/CT.The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scaleInternational validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers.Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classificationFDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0.Positron emission tomography in the management of lymphomas.The role of positron emission tomography in the management of colorectal cancer.The impact of PET scanning on management of paediatric oncology patients.Use of positron emission tomography in evaluation of brachial plexopathy in breast cancer patientsCombination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL.Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.Effect of Bayesian-penalized likelihood reconstruction on [13N]-NH3 rest perfusion quantification.Opportunistic infection and nuclear medicine.Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses.When should FDG-PET be used in the modern management of lymphoma?Radiation exposure of the families of outpatients treated with radioiodine (iodine-131) for hyperthyroidism.PET-CT in the UK: current status and future directions.Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas.Association between hypoxic volume and underlying hypoxia-induced gene expression in oropharyngeal squamous cell carcinoma.Training improves the interobserver agreement of the expert positron emission tomography review panel in primary mediastinal B-cell lymphoma: interim analysis in the ongoing International Extranodal Lymphoma Study Group-37 study.The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy.Analysis of loco-regional failures in head and neck cancer after radical radiation therapy.Cost-effectiveness of preoperative positron emission tomography in ischemic heart disease.Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement.FDG-PET as a biomarker for early response in diffuse large B-cell lymphoma as well as in Hodgkin lymphoma? Ready for implementation in clinical practice?CXCR2 Inhibition - a novel approach to treating CoronAry heart DiseAse (CICADA): study protocol for a randomised controlled trial.Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3-5 October 2012.Bone mineral densitometry in clinical practice. Differences in reference values are important.Intractable hiccups causing avid FDG uptake in the muscles of respiration.FDG-PET maximum standardised uptake value is associated with variation in survival: analysis of 498 lung cancer patients.Measurement of the internal dose to families of outpatients treated with 131I for hyperthyroidism.All that glitters is not gold - new reconstruction methods using Deauville criteria for patient reporting.Guidelines for the use of imaging in the management of patients with myeloma.18F-FDG PET/CT in Lymphoma: Has Imaging-Directed Personalized Medicine Become a Reality?Therapeutic implications of thymic uptake of radioiodine in thyroid carcinoma.
P50
Q26752284-0F0A4996-498B-45FF-AC31-5387FBA6DA4CQ30242020-5595B0CD-8807-4FCD-A9A9-02E7D404619AQ30777844-034EBAD2-C336-4B93-A182-5F1F5FA94642Q33415305-EA88D3C6-99AD-4524-921C-B04D6558F186Q33696003-2A4541BB-4235-45C7-A6B9-D45F92BF6E13Q34334369-EBB3FB35-DD99-4D51-8F61-066AA1D939A7Q34663865-6DD650D2-3AEA-4F4D-80DD-1726732106CDQ35043725-EC691E8E-4F86-4E5A-AF75-6F8E6D5BFF64Q35055914-E775BE75-8052-47DC-B998-9A3AF2077D51Q35615005-0EAE13F9-17D5-4F4F-8146-DC5889A5EB81Q35854149-DCBA2F86-D572-4E7A-BABA-B6D3C0F75599Q36618126-36551ACB-F25D-4AD6-AD36-8F407989F1ABQ36897012-8379AB1B-8308-4C29-8DF5-D42BEB49E3BFQ37126978-16EDCA4E-A570-4AB3-B088-15D415CBA6ABQ37240835-B30DFC1E-4A7A-44AA-A72A-AA3E8E536583Q37375799-3F23AE87-B095-4701-82FE-C9A5B053FE56Q37383721-EDF7A1C6-4D35-4BFC-B2F1-513CE7569820Q37821961-A2F1F097-7A78-4132-A2D3-DCCCB17CEBEAQ38153086-9B51587F-2A3F-4248-AA83-F4C1FCD9DBD4Q38578351-5DF0E6DF-BF15-47C3-ACBC-EFBDC2E86326Q38798179-4490FA0B-4098-465C-B702-77F8646AAF33Q38826522-4084B8A2-BA99-44C7-88E7-28B59AC69526Q38836081-E3234D49-DDB3-414F-B8C7-A6BA07FD3007Q38889339-871C14DC-03D3-467D-8145-9A7F46277780Q38933091-13154024-F50F-4648-9733-3AB4789D2E01Q38941888-8CF140B0-E1E0-4C15-8AE7-144CB957DDB2Q38949439-8BA428EB-901C-4E36-8AAF-91C26DB8F5F6Q39097731-56C344BB-AE7B-46CD-A660-5F14873C30A4Q39342393-84514CAA-DF23-423A-B8B5-5A363B15D420Q42362028-94E41D69-7930-4120-8A46-C12F87FDB19BQ42375183-38E38A6C-AB76-4FB1-966E-6145CAD10417Q42603371-B9B3BE2C-1073-46FC-9D2E-F42B7973F909Q42909430-54913EB5-6BCA-423A-87A4-33C69FD6811BQ43281610-B1EDA2E1-5E48-4AA2-A2CA-57641FAE345CQ44762173-5997E1F5-C522-424B-9DCC-2F444C306438Q46704834-4B480001-A2E0-4D4C-8E5B-7AA7D1D9DD29Q47290192-396879CE-7852-482A-B191-87EDD9942F64Q47329918-10DB1255-84C2-4903-A0E1-DB3BBB67E17AQ47808320-764DEF93-AEBE-419E-89C6-DAA6CB21E180Q47998374-2709360D-91C9-44B2-A9D4-52F39D7EE8D9
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Sally Barrington
@ast
Sally Barrington
@en
Sally Barrington
@es
Sally Barrington
@nl
Sally Barrington
@sl
type
label
Sally Barrington
@ast
Sally Barrington
@en
Sally Barrington
@es
Sally Barrington
@nl
Sally Barrington
@sl
prefLabel
Sally Barrington
@ast
Sally Barrington
@en
Sally Barrington
@es
Sally Barrington
@nl
Sally Barrington
@sl
P106
P21
P31
P496
0000-0002-2516-5288